Rimeporide

Rimeporide
Clinical data
ATC code	none;
Legal status
Legal status	Experimental;
Identifiers
	IUPAC name N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine;
CAS Number	187870-78-6;
PubChem CID	9799487;
ChemSpider	7975252;
UNII	QH6B4V5743;
ChEMBL	ChEMBL2107802;
CompTox Dashboard (EPA)	DTXSID30870177 ;
Chemical and physical data
Formula	C11H15N3O5S2
Molar mass	333.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C;
	InChI InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15); Key:GROMEQPXDKRRIE-UHFFFAOYSA-N;

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.^[1] it has been granted orphan drug status by the European Medicines Agency.^[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1 (NHE-1). While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces sodium and calcium overload in cells of Duchenne patients.^[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was unsuccessful in Phase I clinical trials, but was tolerated well by volunteers. Subsequently, the drug was sold to EspeRare, a Swiss nonprofit organisation^[3] that aims at developing drugs for rare diseases. As of May 2015^[update], the substance is in preclinical development for Duchenne.^[1]

References

^ ^a ^b ^c Spreitzer, Helmut (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.
^ "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
^ "Our mission and vision". EspeRare. Retrieved 23 July 2015.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[ÖAZ-1] Spreitzer, Helmut (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.

[Orphan-2] "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.

[EspeRare-3] "Our mission and vision". EspeRare. Retrieved 23 July 2015.

[1]

[2]

[3]

Rimeporide

Mechanism of action

History

See also

Other drugs for Duchenne muscular dystrophy

References